Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease

Summary

Parkinson's disease (PD) is one of the most common neurodegenerative diseases characterized by the progressive loss of dopaminergic (DA) neurons in the substantia nigra compacta (SNc) and aggregation of Lewy bodies in neurons. Although aging, oxidative damage and neuroinflammation have been recognized to play crucial roles in the pathogenesis of PD, the precise etiology remains obscure. Emerging evidence suggests PD is a systemic metabolic disease, and metabolic abnormality correlates with functional alternations in PD

Timeline

Start

2023-01-06

Primary completion

2025-01-20

Completion

2025-01-20

Publications

• AlRasheed HA, Bahaa MM, Elmasry TA, Elberri EI, Kotkata FA, El Sabaa RM, Elmorsi YM, Kamel MM, Negm WA, Hamouda AO, Aldossary KM, Salahuddin MM, Yasser M, Eldesouqui M, Hamouda MA, Eltantawy N, Elawady ME, Abdallah MS. Randomized, double-blind, placebo-controlled pilot study of metformin as an adjunctive therapy in Parkinson's disease. Front Pharmacol. 2025 May 2;16:1497261. doi: 10.3389/fphar.2025.1497261. eCollection 2025.

Drugs

Indications